耗材描述
Bevacizumab (PBS)
产品活性:Bevacizumab 是一种人源化的 IgG1 单克隆抗体,高亲和力且特异性地与所有 VEGF-A 结合。
产品来源: https://www.medchemexpress.cn/bevacizumab-pbs.html
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:VEGFR
In Vitro: Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.
In Vivo: It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01).
相关产品:Sorafenib | Lenvatinib | Bevacizumab | Regorafenib | Sunitinib | Nintedanib | Semaxinib | Cabozantinib | Ponatinib | Axitinib | Midostaurin | Chloramphenicol | Pazopanib | Glycine | PD173074 | Tanshinone IIA | Fruquintinib | 5Z-7-Oxozeaenol | Vandetanib | SU 5402 | Linifanib | Foretinib | SPHINX31 | Ripretinib | GW806742X | Dovitinib
品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物;10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;设有专业的实验中心和严格的质控、验证体系;提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;产品的生物活性多经各国客户实验验证;Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;与世界各大制药公司及知名科研机构建立了长期的合作。